Zolinza FDA Approval History
FDA Approved: Yes (First approved October 6, 2006)
Brand name: Zolinza
Generic name: vorinostat
Dosage form: Capsules
Company: Merck & Co., Inc.
Treatment for: Cutaneous T-cell Lymphoma
Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.
Development timeline for Zolinza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.